Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections

Antibody-mediated immunity directed against Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is an important immune mechanism for protection against clinical malaria and control of parasitemia. Current studies on PfEMP1-based immunity are constrained by the protein's high molecular weight, complex multidomain architecture, and extensive polymorphism. Controlled human malaria infection (CHMI) studies uniquely enable the assessment of strain-specific PfEMP1 immunity prior to exposure and its correlation with infection outcomes using the same parasite strain. In this study, different serological assays targeting both full-length native PfEMP1 and individual domains were applied to plasma samples obtained prior to challenge infection at study baseline from 25 individuals enrolled in a CHMI study of PfSPZ Challenge (NF54), that included malaria-naïve Europeans and lifelong malaria-exposed Africans with varying degrees of immunity. All assays showed strong predictive value of both PfEMP1 antibody levels and breadth at study baseline for CHMI outcome. A random forest machine learning analysis of antibody recognition profiles, measured by AlphaScreen nearly covering all extracellular PfEMP1 domains of the NF54-CHMI parasite strain, suggested that a broad antibody repertoire, including antibodies against the most diversified group B PfEMP1s, represents a discriminative feature distinguishing volunteers with high versus low susceptibility to CHMI. In parasites re-isolated from the volunteers, dominant var transcripts encoded PfEMP1 variants are not recognized by the individuals' pre-existing antibodies at study baseline. Given that the CHMI strain NF54 predominantly expresses B-type var genes at the onset of blood-stage infection, effective control of CHMI was associated with a broad antibody repertoire, particularly including antibodies targeting B-type PfEMP1. In line with the "hole-in-the-wall" theory, this likely reflects an antibody-mediated restriction of the parasite population emerging from the liver to parasites expressing PfEMP1 variants not previously encountered by the host immune system.

Authors

Institutions

Publication Details

Journal
PLoS Pathogens
Published
2026-06-24
DOI
https://doi.org/10.1371/journal.ppat.1014377
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections

Stephen L. Hoffman, Eizo Takashima, Meral Esen, Iris Bruchhaus et al.
PLoS Pathogens
Malaria Research and Control
article

Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections

Stephen L. Hoffman, Eizo Takashima, Meral Esen, Iris Bruchhaus, Tim‐Wolf Gilberger, Takafumi Tsuboi, Anna Bachmann, Charlotte Wapler, Jean Claude Dejon-Agobé, Hannah Honner, Benjamin Mordmüller, B. Kim Lee Sim, Ralf Krumkamp, Thomas Lavstsen, Hikaru Nagaoka, Jana Held, Peter G. Kremsner, Jeannot Fréjus Zinsou, Yabo J. Honkpehedji, Louise Turner, Bertrand Lell, Yannick D. Höppner, Heidrun von Thien
article en

Abstract

Antibody-mediated immunity directed against Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is an important immune mechanism for protection against clinical malaria and control of parasitemia. Current studies on PfEMP1-based immunity are constrained by the protein's high molecular weight, complex multidomain architecture, and extensive polymorphism. Controlled human malaria infection (CHMI) studies uniquely enable the assessment of strain-specific PfEMP1 immunity prior to exposure and its correlation with infection outcomes using the same parasite strain. In this study, different serological assays targeting both full-length native PfEMP1 and individual domains were applied to plasma samples obtained prior to challenge infection at study baseline from 25 individuals enrolled in a CHMI study of PfSPZ Challenge (NF54), that included malaria-naïve Europeans and lifelong malaria-exposed Africans with varying degrees of immunity. All assays showed strong predictive value of both PfEMP1 antibody levels and breadth at study baseline for CHMI outcome. A random forest machine learning analysis of antibody recognition profiles, measured by AlphaScreen nearly covering all extracellular PfEMP1 domains of the NF54-CHMI parasite strain, suggested that a broad antibody repertoire, including antibodies against the most diversified group B PfEMP1s, represents a discriminative feature distinguishing volunteers with high versus low susceptibility to CHMI. In parasites re-isolated from the volunteers, dominant var transcripts encoded PfEMP1 variants are not recognized by the individuals' pre-existing antibodies at study baseline. Given that the CHMI strain NF54 predominantly expresses B-type var genes at the onset of blood-stage infection, effective control of CHMI was associated with a broad antibody repertoire, particularly including antibodies targeting B-type PfEMP1. In line with the "hole-in-the-wall" theory, this likely reflects an antibody-mediated restriction of the parasite population emerging from the liver to parasites expressing PfEMP1 variants not previously encountered by the host immune system.

PLoS PathogensVol. 22(6)
University of Copenhagen (DK), Radboud University Nijmegen (NL), Universität Hamburg (DE), Leiden University Medical Center (NL), Copenhagen University Hospital (DK), Radboud University Medical Center (NL), Sanaria (US), Centre de Recherche Médicales de Lambaréné (GA), Radboud Institute for Molecular Life Sciences (NL), German Center for Infection Research (DE), Centre for Structural Systems Biology (DE), Ehime University (JP), Medical University of Vienna (AT), University of Tübingen (DE), Bernhard Nocht Institute for Tropical Medicine (DE)
Deutsches Zentrum für Infektionsforschung, Japan Agency for Medical Research and Development, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Novo Nordisk, Danmarks Frie Forskningsfond, Kirsten og Freddy Johansens Fond, Novo Nordisk Fonden, National Institutes of Health, National Institute of Allergy and Infectious Diseases, European and Developing Countries Clinical Trials Partnership
Reduced inequalities
Openalex Percentile: Top 6%
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.